R01MH126940
Project Grant
Overview
Grant Description
Distinct Steroid Mechanisms in Menstrual Cycle Exacerbation of Psychopathology - Summary
Changes in reproductive hormones across the menstrual cycle may be a key biological source of symptom variability in psychopathology. Strong individual differences in neural sensitivity to normal hormone changes can result in lability of a wide range of emotional, interpersonal, and behavioral symptoms. However, the biobehavioral mechanisms underlying these effects are not yet well understood.
Borderline Personality Disorder (BPD) is a severe and costly psychiatric condition comprising labile symptoms across many domains of functioning. Our pilot data suggest three distinct biologically based mechanisms may produce cycle-based symptom exacerbation, contributing to symptom lability:
1) Reactive and interpersonal symptoms due to irritability from changes in progesterone (P4) levels.
2) Depressive symptoms due to impaired cognitive functioning and increased rumination during estrogen (E2) withdrawal.
3) Risk-taking symptoms due to increased reward responsiveness during E2 peaks (ovulation).
The objectives of this research are to test a model of three RDOC-consistent biologically based mechanisms underlying how the menstrual cycle exacerbates psychopathology. A sample of 170 women ages 18 to 45 with ≥3 BPD symptoms will be recruited from specialized clinical services and social media. Participants will be comprehensively assessed for BPD and exclusion criteria (e.g., use of hormone-based medication or hormonal conditions).
Participants will complete well-established assessment measures of BPD and other psychopathological symptoms and diagnoses during a baseline laboratory visit within the first few days of the start of their menstrual cycle. Then, they will provide complete questionnaires about BPD symptoms and proposed mechanisms every evening for two complete cycles. During one cycle, they will complete tasks targeted to key cycle phases, based on menses onset and ovulation test results, and daily urine samples for hormone assay each morning.
Specific Aims:
Aim 1 is to evaluate whether shifts in hormones across the cycle predict within-person changes in symptoms consistent with the proposed triadic hormone sensitivity theory, with rising levels of P4 predicting increases in rejection sensitivity, interpersonal conflict, and impulsive reactivity to stress, decreasing levels of E2 predicting increases in depression, hopelessness, and suicidal ideation, and peaks in E2 (ovulation) predicting increases in proactive aggression and substance misuse.
Aim 2 is to evaluate whether proposed psychological mechanisms mediate associations between hormonal changes and symptom effects, with increased irritability expected to mediate P4 effects, decreased cognitive functioning expected to mediate E2 withdrawal effects, especially for individuals with greater rumination-proneness, and increased reward responsiveness expected to mediate ovulatory effects.
An exploratory Aim 3 will examine the extent to which the presence of these three forms of hormone sensitivity are associated. Findings will inform the development of individualized, transdiagnostic interventions to mitigate the impact of cycle-based symptom exacerbation.
Changes in reproductive hormones across the menstrual cycle may be a key biological source of symptom variability in psychopathology. Strong individual differences in neural sensitivity to normal hormone changes can result in lability of a wide range of emotional, interpersonal, and behavioral symptoms. However, the biobehavioral mechanisms underlying these effects are not yet well understood.
Borderline Personality Disorder (BPD) is a severe and costly psychiatric condition comprising labile symptoms across many domains of functioning. Our pilot data suggest three distinct biologically based mechanisms may produce cycle-based symptom exacerbation, contributing to symptom lability:
1) Reactive and interpersonal symptoms due to irritability from changes in progesterone (P4) levels.
2) Depressive symptoms due to impaired cognitive functioning and increased rumination during estrogen (E2) withdrawal.
3) Risk-taking symptoms due to increased reward responsiveness during E2 peaks (ovulation).
The objectives of this research are to test a model of three RDOC-consistent biologically based mechanisms underlying how the menstrual cycle exacerbates psychopathology. A sample of 170 women ages 18 to 45 with ≥3 BPD symptoms will be recruited from specialized clinical services and social media. Participants will be comprehensively assessed for BPD and exclusion criteria (e.g., use of hormone-based medication or hormonal conditions).
Participants will complete well-established assessment measures of BPD and other psychopathological symptoms and diagnoses during a baseline laboratory visit within the first few days of the start of their menstrual cycle. Then, they will provide complete questionnaires about BPD symptoms and proposed mechanisms every evening for two complete cycles. During one cycle, they will complete tasks targeted to key cycle phases, based on menses onset and ovulation test results, and daily urine samples for hormone assay each morning.
Specific Aims:
Aim 1 is to evaluate whether shifts in hormones across the cycle predict within-person changes in symptoms consistent with the proposed triadic hormone sensitivity theory, with rising levels of P4 predicting increases in rejection sensitivity, interpersonal conflict, and impulsive reactivity to stress, decreasing levels of E2 predicting increases in depression, hopelessness, and suicidal ideation, and peaks in E2 (ovulation) predicting increases in proactive aggression and substance misuse.
Aim 2 is to evaluate whether proposed psychological mechanisms mediate associations between hormonal changes and symptom effects, with increased irritability expected to mediate P4 effects, decreased cognitive functioning expected to mediate E2 withdrawal effects, especially for individuals with greater rumination-proneness, and increased reward responsiveness expected to mediate ovulatory effects.
An exploratory Aim 3 will examine the extent to which the presence of these three forms of hormone sensitivity are associated. Findings will inform the development of individualized, transdiagnostic interventions to mitigate the impact of cycle-based symptom exacerbation.
Awardee
Funding Goals
THE MISSION OF THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) IS TO TRANSFORM THE UNDERSTANDING AND TREATMENT OF MENTAL ILLNESSES THROUGH BASIC AND CLINICAL RESEARCH, PAVING THE WAY FOR PREVENTION, RECOVERY, AND CURE. WE FULFILL THIS MISSION BY SUPPORTING AND CONDUCTING RESEARCH ON MENTAL ILLNESSES, HEALTH SERVICES, AND THE UNDERLYING BASIC SCIENCE OF THE BRAIN AND BEHAVIOR; SUPPORTING THE TRAINING OF SCIENTISTS TO CARRY OUT BASIC AND CLINICAL MENTAL HEALTH RESEARCH; AND COMMUNICATING WITH SCIENTISTS, PATIENTS, PROVIDERS, AND THE PUBLIC ABOUT MENTAL HEALTH RESEARCH ADVANCES AND PRIORITIES. IN MAY 2024, NIMH RELEASED ITS STRATEGIC PLAN FOR RESEARCH. THE STRATEGIC PLAN BUILDS ON THE SUCCESSES OF PREVIOUS NIMH STRATEGIC PLANS BY PROVIDING A FRAMEWORK FOR SCIENTIFIC RESEARCH AND EXPLORATION, AND ADDRESSING NEW CHALLENGES IN MENTAL HEALTH.THE NEW STRATEGIC PLAN OUTLINES FOUR HIGH-LEVEL GOALS: GOAL 1: DEFINE THE BRAIN MECHANISMS UNDERLYING COMPLEX BEHAVIORS GOAL 2: EXAMINE MENTAL ILLNESS TRAJECTORIES ACROSS THE LIFESPAN GOAL 3: STRIVE FOR PREVENTION AND CURES GOAL 4: STRENGTHEN THE PUBLIC HEALTH IMPACT OF NIMH-SUPPORTED RESEARCH THESE FOUR GOALS FORM A BROAD ROADMAP FOR THE INSTITUTES RESEARCH PRIORITIES OVER THE NEXT FIVE YEARS, BEGINNING WITH THE FUNDAMENTAL SCIENCE OF THE BRAIN AND BEHAVIOR, AND EXTENDING THROUGH EVIDENCE-BASED SERVICES THAT IMPROVE PUBLIC HEALTH OUTCOMES.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Providence,
Rhode Island
029120001
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 05/31/26 to 05/31/27 and the total obligations have increased 857% from $320,000 to $3,060,986.
Brown University was awarded
Menstrual Cycle & Psychopathology: Understanding Distinct Steroid Mechanisms
Project Grant R01MH126940
worth $3,060,986
from the National Institute of Mental Health in July 2021 with work to be completed primarily in Providence Rhode Island United States.
The grant
has a duration of 5 years 10 months and
was awarded through assistance program 93.242 Mental Health Research Grants.
The Project Grant was awarded through grant opportunity NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 4/6/26
Period of Performance
7/15/21
Start Date
5/31/27
End Date
Funding Split
$3.1M
Federal Obligation
$0.0
Non-Federal Obligation
$3.1M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for R01MH126940
Transaction History
Modifications to R01MH126940
Additional Detail
Award ID FAIN
R01MH126940
SAI Number
R01MH126940-2614307678
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75N700 NIH National Institute of Mental Health
Funding Office
75N700 NIH National Institute of Mental Health
Awardee UEI
E3FDXZ6TBHW3
Awardee CAGE
23242
Performance District
RI-01
Senators
Sheldon Whitehouse
John Reed
John Reed
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Mental Health, National Institutes of Health, Health and Human Services (075-0892) | Health research and training | Grants, subsidies, and contributions (41.0) | $893,819 | 74% |
| National Institute of General Medical Sciences, National Institutes of Health, Health and Human Services (075-0851) | Health research and training | Grants, subsidies, and contributions (41.0) | $320,000 | 26% |
Modified: 4/6/26